Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment

MT Newswires Live12-09

Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.

Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.

The data also showed the inducement of "robust, durable production of fetal hemoglobin," the company said.

Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.

BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490749299?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490749299","market":"us","top_or_hot":-1,"title":"Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.</p><p>Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.</p><p>The data also showed the inducement of \"robust, durable production of fetal hemoglobin,\" the company said.</p><p>Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.</p><p>BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Says Conditioning Platform Shows Potential in Sickle Cell Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 17:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490749299","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490749299","pubTimestamp":1733737406,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Beam Therapeutics  said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.The data also showed the inducement of \"robust, durable production of fetal hemoglobin,\" the company said.Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BEAM":"Beam Therapeutics, Inc.","BK4588":"碎股","BK4505":"高瓴资本持仓","LENZ":"Therapeutics","BK4535":"淡马锡持仓","BK4585":"ETF&股票定投概念","BK4556":"基因编辑"},"translate_title":"Beam Therapeutics表示调理平台在镰状细胞病治疗方面显示出潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":0.9},"content_text":"Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model.Engraftment is the process under which transplanted stem cells enter the bloodstream, reach the bone marrow, and produce new blood cells.The data also showed the inducement of \"robust, durable production of fetal hemoglobin,\" the company said.Beam Therapeutics said its platform uses two investigational drug products to provide a non-genotoxic alternative to traditional transplant medicines: the BEAM-103 antibody and the BEAM-104 cell therapy. The company plans to advance the two candidates in sickle cell disease and beta-thalassemia, which are blood disorders.BEAM-103 dosing was well tolerated, with no need for antibiotics or additional supportive care, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490749299"}